Skyrizi (AbbVie) is expected to face US biosimilar competition from 2033. AbbVie 10-K: US composition-of-matter patents expire 2033.
Skyrizi's US exclusivity date is based on company guidance. The date comes from the company's own filings or guidance. Secondary patents, new formulations or litigation can still move it. It is a biologic, so copies are biosimilars. Biosimilars are harder to make and usually erode sales more gradually than generics.
Skyrizi is 29% of AbbVie's 2025 revenue ($17.6B of $61.2B). With Rinvoq, the drugs tracked here add up to 42% of AbbVie's revenue losing US exclusivity by 2037.
Bars show each company's tracked drugs as a share of its total 2025 revenue. Skyrizi is highlighted.